RxDoctor Payments Data

Shilpa Chitnis, MD

Neurology · Tyler, TXNPI 1578585337

Payments from drug & device makers

$36,876in general payments, 2019–2025

Across 201 payments — averaging $183.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$16K
  • AbbVie$7K
  • Amneal Pharmaceuticals LLC$4K
  • Orphalan Inc$3K
  • Acorda Therapeutics, Inc$2K
  • Neurocrine Biosciences, Inc.$2K
  • plus $3K from 19 others

What the payments were for

  • Consulting fees$14,62340%
  • Speaking & faculty fees$14,74540%
  • Travel & lodging$1,7135%
  • Food & beverage$5,79516%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$36,876 in reported general payments places this provider in the 80th percentile of 1,246 neurology providers in Texas.

See all neurology providers in Texas

Medicare billing

Part B allowed, 2024
$29,274
Medicare patients
114
Services billed
304

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RytaryCarbidopa/Levodopa128$191,938
AustedoDeutetrabenazine12$89,386
Rasagiline Mesylate36$4,063
Carbidopa-LevodopaCarbidopa/Levodopa89$3,500
Carbidopa-Levodopa ErCarbidopa/Levodopa24$2,477
Memantine Hcl12$445
Primidone17$441
Donepezil Hcl14$153
Sertraline Hcl11$149
Clonazepam37$139
Gabapentin15$85
Temazepam15$82

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Amneal Pharmaceuticals LLCRytary$3,982$191,938128 claims
Teva Pharmaceuticals USA, Inc.Austedo$378$89,38612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,246 neurology providers in Texas.

Other neurology in Tyler

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →